292 related articles for article (PubMed ID: 18007660)
1. T-cell death and cancer immune tolerance.
Lu B; Finn OJ
Cell Death Differ; 2008 Jan; 15(1):70-9. PubMed ID: 18007660
[TBL] [Abstract][Full Text] [Related]
2. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
3. [Immune system and tumors].
Terme M; Tanchot C
Ann Pathol; 2017 Feb; 37(1):11-17. PubMed ID: 28159405
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive networks in the tumour environment and their therapeutic relevance.
Zou W
Nat Rev Cancer; 2005 Apr; 5(4):263-74. PubMed ID: 15776005
[TBL] [Abstract][Full Text] [Related]
5. Suppressive influences in the immune response to cancer.
Bronte V; Mocellin S
J Immunother; 2009 Jan; 32(1):1-11. PubMed ID: 19307988
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell biology and its role in tumor immunotherapy.
Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
[TBL] [Abstract][Full Text] [Related]
8. Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells.
Hurwitz AA; Watkins SK
Cancer Immunol Immunother; 2012 Feb; 61(2):289-293. PubMed ID: 22237887
[TBL] [Abstract][Full Text] [Related]
9. Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy.
Zheng R; Kjaergaard J; Lee WT; Cohen PA; Shu S
Cancer Treat Res; 2007; 135():223-37. PubMed ID: 17953420
[No Abstract] [Full Text] [Related]
10. Tumor evasion from T cell surveillance.
Töpfer K; Kempe S; Müller N; Schmitz M; Bachmann M; Cartellieri M; Schackert G; Temme A
J Biomed Biotechnol; 2011; 2011():918471. PubMed ID: 22190859
[TBL] [Abstract][Full Text] [Related]
11. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.
Ahmad M; Rees RC; Ali SA
Cancer Immunol Immunother; 2004 Oct; 53(10):844-54. PubMed ID: 15197495
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
Braza MS; Klein B
Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882
[TBL] [Abstract][Full Text] [Related]
13. The 'kiss of death' by dendritic cells to cancer cells.
Chan CW; Housseau F
Cell Death Differ; 2008 Jan; 15(1):58-69. PubMed ID: 17948029
[TBL] [Abstract][Full Text] [Related]
14. Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.
Wennhold K; Thelen M; Schlößer HA; Haustein N; Reuter S; Garcia-Marquez M; Lechner A; Kobold S; Rataj F; Utermöhlen O; Chakupurakal G; Theurich S; Hallek M; Abken H; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
Cancer Immunol Res; 2017 Sep; 5(9):730-743. PubMed ID: 28778961
[TBL] [Abstract][Full Text] [Related]
15. Tumor-host immune interactions and dendritic cell dysfunction.
Yang L; Carbone DP
Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
[TBL] [Abstract][Full Text] [Related]
16. Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion.
DeVito NC; Plebanek MP; Theivanthiran B; Hanks BA
Front Immunol; 2019; 10():2876. PubMed ID: 31921140
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth.
Lin A; Schildknecht A; Nguyen LT; Ohashi PS
Immunol Lett; 2010 Jan; 127(2):77-84. PubMed ID: 19778555
[TBL] [Abstract][Full Text] [Related]
18. Cellular and molecular mechanisms of tumor-induced T-cell tolerance.
Horna P; Sotomayor EM
Curr Cancer Drug Targets; 2007 Feb; 7(1):41-53. PubMed ID: 17305477
[TBL] [Abstract][Full Text] [Related]
19. Challenges and future perspectives of T cell immunotherapy in cancer.
de Aquino MT; Malhotra A; Mishra MK; Shanker A
Immunol Lett; 2015 Aug; 166(2):117-33. PubMed ID: 26096822
[TBL] [Abstract][Full Text] [Related]
20. Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.
Rolinski J; Hus I
J Immunotoxicol; 2014 Oct; 11(4):311-8. PubMed ID: 24495309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
